Advancing Neurological Therapeutics 2016 | Pre-test

18 Questions | Total Attempts: 49

SettingsSettingsSettings
Please wait...
Advancing Neurological Therapeutics 2016 | Pre-test

This educational program aims to update practitioners on advances in the diagnosis and treatment of Parkinson’s disease, multiple sclerosis, stroke, dementia and related disorders. We will discuss evidence-based management, improvements in therapeutic rehabilitation, and updates on therapeutic theory and practice.


Questions and Answers
  • 1. 
    The 2015 MDS Clinical Diagnostic Criteria for Parkinson’s disease include all of the following EXCEPT:
    • A. 

      Retained motor parkinsonism as the core feature (bradykinesia plus rest tremor or rigidity)

    • B. 

      Postural instability

    • C. 

      Increasing recognition to non-motor manifestations

  • 2. 
    Botulinum toxin is Indicated for all of the following movement disorders EXCEPT
    • A. 

      Sialorrhea

    • B. 

      Dystonia

    • C. 

      Spasticity

    • D. 

      Spasmodic dysphonia

    • E. 

      Motor Neuron Disease

  • 3. 
    Which of the following new agents was the first disease modifying therapy to show positive benefit in primary progressive multiple sclerosis in clinical trials?
    • A. 

      Daclizumab

    • B. 

      Alemtuzumab

    • C. 

      Ocrelizumab

    • D. 

      Siponimod

    • E. 

      Ofatumumab

  • 4. 
    Atrophy of which of the following layers on conventional optical coherence tomography (OCT) has been shown to mirror whole brain atrophy in patients with MS?
    • A. 

      Outer plexiform layer

    • B. 

      Photoreceptor inner segment

    • C. 

      Inner nuclear layer

    • D. 

      Ganglion cell + inner plexiform layer

    • E. 

      Retinal pigment epithelium

  • 5. 
    What is the approximately time from stroke onset to catheter based intervention (thrombectomy) for effectivness? 
    • A. 

      3 hours

    • B. 

      4.5 hours

    • C. 

      6 hours

    • D. 

      7 hours

    • E. 

      12 hours

  • 6. 
    Which therapies are proven to improve outcomes in acute ICH?
    • A. 

      Platelet transfusion

    • B. 

      Acute SBP lowering < 140

    • C. 

      Craniotomy

    • D. 

      IV tPA

    • E. 

      N/A

  • 7. 
    What percentage of Alzheimer disease patients are not informed of their diagnosis?
    • A. 

      10%

    • B. 

      20%

    • C. 

      30%

    • D. 

      40%

    • E. 

      50%

  • 8. 
    Which of the following is true about delivering a difficult diagnosis?
    • A. 

      The provider should avoid betraying an emotional response

    • B. 

      It important to “push past” the patients’ emotional expressions to focus on the facts of the case

    • C. 

      Receiving a negative diagnosis is psychologically harmful to the patient

    • D. 

      Medical terminology should be avoided unless necessary to promote understanding

    • E. 

      The provider should get to the point (the diagnosis and plan) as quickly as possible

  • 9. 
    Which of the following statements is false regarding ATYPICAL forms of AD?
    • A. 

      Patients are generally younger than 65 years

    • B. 

      Atypical patients make up about 40% of AD cases

    • C. 

      Hippocampal atrophy may be absent

    • D. 

      Cortical atrophy may be more focal

  • 10. 
    Amyloid imaging is appropriate in any of the following:
    • A. 

      Patients with persistent or progressive unexplained MCI

    • B. 

      To determine dementia severity

    • C. 

      Patients with progressive dementia and atypically early age of onset (65 years or less in age)

    • D. 

      Asymptomatic individuals

    • E. 

      All of the above

    • F. 

      A and C

    • G. 

      B and D

  • 11. 
    What is the most common early impairment in Alzheimer’s disease?
    • A. 

      Visuospatial

    • B. 

      Executive

    • C. 

      Processing Speed

    • D. 

      Memory

  • 12. 
    What is the most common early cognitive impairment in Parkinson’s disease?
    • A. 

      Visuospatial

    • B. 

      Executive

    • C. 

      Processing Speed

    • D. 

      Memory

  • 13. 
    True of False: Dual Task Testing is vital because it provides more information of real world performance and of potential for adverse events such as falls.
    • A. 

      True

    • B. 

      False

  • 14. 
    Which of the following is NOT a non-motor symptom associated with neurodegenerative disease:
    • A. 

      Depression

    • B. 

      Fatigue

    • C. 

      Tremor

    • D. 

      Apathy

  • 15. 
    Caregiver stress is an under-recognized and undertreated health risk that can lead to poor outcomes for both caregivers and patients with dementia. 
    • A. 

      True

    • B. 

      False

  • 16. 
    What is considered the most common and debilitating symptom per the majority of MS patients in the research? 
    • A. 

      Weakness

    • B. 

      Pain

    • C. 

      Fatigue

    • D. 

      Cognitive impairment

  • 17. 
    Which technology has been well documented in literature to demonstrate functional benefits in voice, articulation and intelligibility?
    • A. 

      SpeechVive

    • B. 

      LSVT

    • C. 

      Expiratory Muscle Trainers

    • D. 

      Buck Rogers Walkie Talkies

  • 18. 
    Which of the following is an unaided communication system?
    • A. 

      Paper and pencil

    • B. 

      Speech generating Device

    • C. 

      Sign Language

    • D. 

      Smartphone

Back to Top Back to top